Vanguard Group’s ABVC BioPharma ABVC Stock Holding History

Vanguard Group’s Portfolio ABVC Stock Details ABVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$613K	Buy	287,937 +20,487	+8%	+$54.9K	﹤0.01%	3902
2025 Q3	$813K	Buy	267,450 +155,917	+140%	+$479K	﹤0.01%	3841
2025 Q2	$248K	Buy	111,533 +64,586	+138%	+$87.9K	﹤0.01%	4053
2025 Q1	$49.8K	Hold	46,947	–	–	﹤0.01%	4193
2024 Q4	$27.7K	Hold	46,947	–	–	﹤0.01%	4244
2024 Q3	$32.1K	Hold	46,947	–	–	﹤0.01%	4273
2024 Q2	$36.3K	Hold	46,947	–	–	﹤0.01%	4312
2024 Q1	$61.5K	Buy	46,947 +19,700	+72%	+$25.5K	﹤0.01%	4290
2023 Q4	$31.6K	Buy	27,247 +8,926	+49%	+$10.5K	﹤0.01%	4411
2023 Q3	$19.1K	Sell	18,321 -20,430	-53%	-$49.4K	﹤0.01%	4499
2023 Q2	$201K	Hold	38,751	–	–	﹤0.01%	4315
2023 Q1	$248K	Buy	38,751 +1,200	+3%	+$8.57K	﹤0.01%	4288
2022 Q4	$235K	Buy	37,551 +37	+0.1%	+$273	﹤0.01%	4279
2022 Q3	$330K	Hold	37,514	–	–	﹤0.01%	4327
2022 Q2	$398K	Hold	37,514	–	–	﹤0.01%	4340
2022 Q1	$1.02M	Buy	37,514 +238	+0.6%	+$6.34K	﹤0.01%	4201
2021 Q4	$1.26M	Buy	37,276 +33,220	+819%	+$1.04M	﹤0.01%	4197
2021 Q3	$94K	Buy	+4,056	New	+$115K	﹤0.01%	4531

Other funds holding ABVC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Vanguard Group's ABVC Position: Q4 2025 in Review

Vanguard Group increased its ABVC BioPharma (ABVC) stake by 7.7% in Q4 2025, buying an estimated $54.9K and bringing the position to 287,937 shares worth $613K. The position accounts for ﹤0.01% of the portfolio, ranked #3902.

Vanguard Group first reported a position in ABVC in Q3 2021 and has held it in 18 quarters since. The position peaked at $1.26M in Q4 2021. 14 funds tracked by Wall St. Rank hold ABVC as of Q4 2025.

Vanguard Group held 287,937 shares of ABVC BioPharma worth $613K as of Q4 2025.
Vanguard Group bought 20,487 ABVC BioPharma shares in Q4 2025, an estimated $54.9K.
ABVC BioPharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3902 holding.
Vanguard Group first reported a position in ABVC BioPharma in Q3 2021 and has held it in 18 quarters since.
Vanguard Group's ABVC BioPharma position peaked at $1.26M in Q4 2021.
14 funds tracked by Wall St. Rank held ABVC BioPharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.